AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-1 receptor type 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P27930

UPID:

IL1R2_HUMAN

Alternative names:

CD121 antigen-like family member B; CDw121b; IL-1 type II receptor; Interleukin-1 receptor beta; Interleukin-1 receptor type II

Alternative UPACC:

P27930; D3DVJ5; Q6LCE6; Q9UE68

Background:

Interleukin-1 receptor type 2 (IL-1R2), also known as CD121 antigen-like family member B, plays a crucial role in the immune response by acting as a non-signaling receptor for IL1A, IL1B, and IL1RN. It effectively reduces IL1B activities by serving as a decoy receptor, preventing IL1B from binding to IL1R1. Additionally, IL-1R2 modulates cellular responses through its association with IL1RAP after IL1B binding, with the secreted form of IL-1R2 preferentially binding IL1B.

Therapeutic significance:

Understanding the role of Interleukin-1 receptor type 2 could open doors to potential therapeutic strategies, especially in modulating immune responses and inflammation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.